ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising pregnancy from conception to birth, today announced the closing of a CHF 60 (USD 60) million Series B preferred equity financing
http://www.obseva.com/news/
Find an actor

Medtec Japan Tokyo 201818.04.2018

The exhibition will take place from 18 to 20 April at the Big Sight Exhibition Centre in Tokyo, Japan. BioAlps will...

Gene Predictis - Tests génétiques pour prévenir les risques liés aux effets adverse

Des tests pour réduire les risques d'effets nocifs liés aux médicaments et à la nutrition. Un article de l'AGEFI
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn